Amgen Inc (AMGN) FY2025Q3 Earning Prediction
Amgen Inc (AMGN) is set to release its FY2025Q3 earnings performance on 11/04 16:01:00 ET in After Hours trading. Consensus forecasts predict a revenue of 8.97B and an earnings per share (EPS) of 5.00 for the FY2025Q3. With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
AI Earnings Prediction
Amgen is predicted to exceed earnings expectations driven by strong product approvals, biosimilar growth, and expanded manufacturing capacity, despite potential R&D cost pressures.
Scenario Analysis
Key Indicators Forecast
No data
Prediction Logic & Rational
Logic & Justification
Fact Data Analysis:
- Key Product Approvals & Expanded Use Cases:
FDA/EU approvals for Tezspire in chronic rhinosinusitis with nasal polyps (CRSwNP) and expanded Repatha indications (removing prior cardiovascular disease requirements) directly support volume growth and revenue upside. These approvals broaden addressable markets and align with AMGN’s rare disease and cardiovascular growth pillars.
Repatha’s Phase 3 VESALIUS-CV trial success (reducing MACE risk in high-risk patients) strengthens its competitive positioning, likely driving prescription momentum.
- Biosimilar Momentum:
- PAVBLU (part of the biosimilar portfolio) shows robust growth, with recent royalty deals (e.g., $885M upfront from Royalty Pharma for Imdelltra royalties) providing near-term cash flow to reinvest in pipeline/R&D.
- Manufacturing Expansion:
- $650M U.S. manufacturing investment supports capacity for volume-driven products (e.g., Repatha, Tezspire), mitigating supply constraints and enabling future growth.
- R&D Cost Concerns:
- Analysts (BofA, Raymond James) highlight rising R&D spending (e.g., obesity drug MariTide trials), which could pressure EPS despite revenue growth. Consensus EPS estimates have already been revised down - 2.0% over 3 months.
- Competitive Threats:
- Disappointing data for Amgen’s OX40 rocatinlimab and competitor Sanofi’s amlitelimab in atopic dermatitis raises questions about the OX40/OX40L class, but this is likely priced in and not directly impacting Q3 results.
Tactical Strategy Recommendations
Trading Strategy
- Bullish Play: Buy near-term calls (e.g., Nov 2025 $300 strike) to capitalize on low expectations (1.5% stock underperformance vs. S&P 500). Upside catalysts include stronger-than-expected Repatha/Tezspire sales.
- Hedge: Pair with puts (e.g., Nov 2025 $280 strike) to mitigate R&D cost risks.
- Long-Term Holders: Hold through earnings; multiple expansions (Piper Sandler’s $342 PT) remain possible if pipeline updates (e.g., obesity drug MariTide) offset near-term margin concerns.
Earnings Surprise Analysis
AMGN Transcript
Amgen's earnings call presents several positive indicators: increased revenue and EPS guidance, strong product development, and a robust biosimilar portfolio. The Q&A session reveals confidence in pipeline expansions and market opportunities, despite some unclear responses. The raised guidance and strong financial metrics are likely to positively influence the stock price, while the lack of market cap data suggests a moderate impact, leading to a positive sentiment prediction.
AMGN Slides
AMGN Report
Frequently Asked Questions
What is the Amgen Inc FY2025Q3 Earnings Release Date and Time?
Amgen Inc (AMGN) is scheduled to release its FY2025Q3 earnings report onNov 4, 2025, After Hours(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
What Are the Consensus Forecasts for Amgen Inc FY2025Q3 Revenue and EPS?
Analysts' consensus predicts 8.97B in revenue and an EPS of 5.00 for Amgen Inc's FY2025Q3.
What Does Intellectia's AI Predict for Amgen Inc FY2025Q3 Earnings?
Intellectia's exclusive AI algorithms forecast a Beat forAmgen Inc's FY2025Q3 earnings, with a prediction date of Nov 4, 2025. Amgen Inc Amgen is predicted to exceed earnings expectations driven by strong product approvals, biosimilar growth, and expanded manufacturing capacity, despite potential R&D cost pressures.
How Can I Use This Earnings Prediction to Trade AMGN Stock?
Leverage Intellectia's AI forecast to position trades ahead of theNov 4, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
How Accurate Is Intellectia's AI for Earnings Predictions Like Amgen Inc FY2025Q3?
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
How does AI Earnings Prediction generate its forecasts?
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
When are the predictions available, and how often are they updated?
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Can I use AI Earnings Prediction for all types of stocks?
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2025-2026 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
